Adenosine deaminase gene therapy

Drug Profile

Adenosine deaminase gene therapy

Latest Information Update: 29 Aug 2007

Price : $50

At a glance

  • Originator Genetic Therapy; National Institute of Health and Nutrition
  • Class Gene therapies
  • Mechanism of Action Adenosine deaminase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Adenosine deaminase deficiency

Most Recent Events

  • 20 Jun 2003 Data presented at the 6th Annual Meeting of the American Society of Gene Therapy (ASGT-2003) have been added to the Metabolic disorders therapeutic trials section ,
  • 29 Apr 2003 A study has been added to the Metabolic disorders therapeutic trials section
  • 03 Oct 2002 Suspended - Phase-I for Adenosine deaminase deficiency in USA (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top